Glossary
Triple Agonist
A triple agonist switches on GIP, GLP-1 and glucagon receptors from a single backbone. Why a third arm was added, and what published research has examined.
Triple agonists are single peptides designed to activate three receptors. In metabolic peptide research the trio is nearly always GIP, GLP-1 and the glucagon receptor, built on a proglucagon-family template and stabilised with Aib substitutions plus a fatty-acid chain that binds albumin.
The reason for a third receptor
The two incretin components provide glucose-dependent insulin signalling and effects on appetite; the glucagon component contributes a reported rise in energy expenditure and hepatic lipid oxidation that neither incretin delivers. The engineering challenge is that glucagon receptor activation increases glucose output from the liver, so incretin potency has to be weighted strongly enough to counterbalance it. The real technical task is finding that balance, not the mere addition of a third receptor.
The best-known example
Retatrutide is the triple agonist studied most extensively, with human trial results published for the investigational medicine through phase 2 and on into phase 3. Those findings concern the clinical candidate under its own trial protocol, not research-grade material with the same sequence.
Related terms
dual agonist · incretin. Compare in Retatrutide vs Tirzepatide, or browse GLP-1 and incretin peptides.